Photo of Neelima Vidula,  MD

Neelima Vidula, MD

Massachusetts General Hospital

Massachusetts General Hospital

Neelima Vidula, MD

Massachusetts General Hospital

EDUCATIONAL TITLES

  • Instructor, Medicine, Harvard Medical School
  • Breast Medical Oncologist, Hematology and Medical Oncology, Massachusetts General Hospital

DF/HCC PROGRAM AFFILIATION

Research Abstract

Neelima Vidula, M.D. is a breast medical oncologist at Massachusetts General Hospital (MGH). She strives to provide outstanding patient care, and incorporate the latest data and newest therapies in treatment plans for patients. Dr. Vidula completed medical school and residency in internal medicine at Northwestern University in Chicago, IL, and a fellowship in hematology and medical oncology at the University of California San Francisco in San Francisco, CA.

Dr. Vidula is the principal investigator of many early phase clinical trials studying novel agents for patients with breast cancer. Among these trials, she is the national co-principal investigator of a multi-center study she designed with immunotherapy and chemotherapy for chest wall disease, which she is leading at multiple sites across the country including MGH through the Translational Breast Cancer Research Consortium. She was recently awarded a prestigious Pfizer ASPIRE award for a study she designed to evaluate a PARP inhibitor in patients with somatic BRCA mutant metastatic breast cancer. Dr. Vidula also performs clinical research evaluating the impact of biomarkers on therapy response and patient outcomes, and conducts research in precision medicine using cell-free DNA and tumor genotyping. She has presented her research at several national and international meetings, and published articles in high-impact journals. She also enjoys teaching medical students, residents, and fellows.

Publications

Powered by Harvard Catalyst
  • Drago JZ, Formisano L, Juric D, Niemierko A, Servetto A, Wander SA, Spring LM, Vidula N, Younger J, Peppercorn J, Yuen M, Malvarosa G, Sgroi D, Isakoff SJ, Moy B, Ellisen LW, Iafrate AJ, Arteaga CL, Bardia A. Amplification Mediates Endocrine Resistance but Retains TORC Sensitivity in Metastatic Hormone Receptor-Positive (HR) Breast Cancer. Clin Cancer Res 2019. PubMed
  • Vidula N, Yau C, Wolf D, Rugo HS. Androgen receptor gene expression in primary breast cancer. NPJ Breast Cancer 2019; 5:47. PubMed
  • Medford AJ, Dubash TD, Juric D, Spring L, Niemierko A, Vidula N, Peppercorn J, Isakoff S, Reeves BA, LiCausi JA, Wesley B, Malvarosa G, Yuen M, Wittner BS, Lawrence MS, Iafrate AJ, Ellisen L, Moy B, Toner M, Maheswaran S, Haber DA, Bardia A. Blood-based monitoring identifies acquired and targetable driver mutations in endocrine-resistant metastatic breast cancer. NPJ Precis Oncol 2019; 3:18. PubMed
  • Vidula N, Rugo HS. Emerging data on improving response to hormone therapy: the role of novel targeted agents. Expert Rev Anticancer Ther 2018; 18:3-18. PubMed
  • Vidula N, Bardia A. Targeted therapy for metastatic triple negative breast cancer: The next frontier in precision oncology. 2018; 8:106167-106168. PubMed
  • Vidula N, Yau C, Li J, Esserman LJ, Rugo HS. Receptor activator of nuclear factor kappa B (RANK) expression in primary breast cancer correlates with recurrence-free survival and development of bone metastases in I-SPY1 (CALGB 150007/150012; ACRIN 6657). Breast Cancer Res Treat 2018; 165:129-138. PubMed
  • Vidula N, Rugo HS. Cyclin-Dependent Kinase 4/6 Inhibitors for the Treatment of Breast Cancer: A Review of Preclinical and Clinical Data. Clin Breast Cancer 2019; 16:8-17. PubMed
  • Rugo HS, Vidula N, Ma C. Improving Response to Hormone Therapy in Breast Cancer: New Targets, New Therapeutic Options. Am Soc Clin Oncol Educ Book 2018; 35:e40-54. PubMed
  • Vidula N, Villa M, Helenowski IB, Merchant M, Jovanovic BD, Meagher R, Mehta J, Singhal S, Winter JN, Frankfurt O, Altman JK, Williams SF, Gordon LI. Adverse Events During Hematopoietic Stem Cell Infusion: Analysis of the Infusion Product. Clin Lymphoma Myeloma Leuk 2015; 15:e157-62. PubMed
  • Vidula N, Rugo HS. Translating the molecular message of triple-negative breast cancer into targeted therapy. Clin Cancer Res 2018; 21:1511-3. PubMed
  • Vidula N, Johnson M, Didwania A. Therapeutic case conference from Northwestern: an elderly gentleman with an unsteady gait. Am J Ther 2012; 19:199-203. PubMed
  • Moinnes JJ, Vidula N, Halim N, Othman SF. Ultrasound accelerated bone tissue engineering monitored with magnetic resonance microscopy. Conf Proc IEEE Eng Med Biol Soc 2018; 1:484-8. PubMed
  • Vidula N, Qamar N, Kurahashi C, Chadha V, Evans D, Peters A. Encephalopathy and strokes secondary to drug reaction with eosinophilia and systemic symptoms: a case report. J Allergy Clin Immunol Pract 2014; 2:222-4. PubMed
Hide